Mergers & acquisitions
Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).
New York-based Ovid Therapeutics and Healx have entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
Fujifilm announced that it is acquiring Atara Biotherapeutics’ cell therapy manufacturing facility in California for $100 million.
Psychedelic-focused drug company Eleusis is merging with Silver Spike Acquisition Corp. II, a special purposes acquisition company, and heading to the Nasdaq with a combined enterprise value of $446 million.
PRESS RELEASES